Fatigue in patients receiving chemotherapy: Patterns of change

Alison Richardson, Ph.D., M.Sc., B.N., R.G.N, P.G.D.E., R.N.T., Emma Ream, M.Sc., B.Sc., R.G.N., and Jenifer Wilson-Barnett, Ph.D., M.Sc., B.A., R.G.N., R.N.T., F.R.C.N.

In volume 21, number 1 of Cancer Nursing, the legend for Figure 3 in the above-named article should have included the following information. The publisher apologizes for this mistake and any inconvenience caused.

FIG. 3. Pattern of smooth mean fatigue score by protocol. (A) CMF (n = 5); (B) Epirubicin and etoposide (n = 16); (C) Carboplatin (n = 21); (D) CEOP (n = 14); (E) Cisplatin and 5-Fu (n = 6); (F) ECF (n = 21); (G) 5-Fu and Levamisole (n = 9); (H) 5-FU weekly (n = 7).